Soft tissue sarcoma
MONDO:0018078A malignant neoplasm arising from muscle tissue, adipose tissue, blood vessels, fibrous tissue, or other supportive tissues excluding the bones.
Also known as: malignant soft tissue tumor, malignant soft tissue tumour, connective tissue sarcoma, malignant mesenchymal tumor, malignant mesenchymal tumour, non-Rhabdo. soft tissue sarcoma, sarcoma of soft tissue, sarcoma of the soft tissue
3364 clinical trials for this condition and its sub-types, 296 tagged with Soft tissue sarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Soft tissue sarcoma
-
Rhabdomyosarcoma 99 trials · 113 incl. sub-types
20 sub-types
- Alveolar rhabdomyosarcoma 9 trials
- Pleomorphic rhabdomyosarcoma 7 trials Sub-types →
- Embryonal rhabdomyosarcoma 4 trials Sub-types →
- Spindle cell rhabdomyosarcoma 3 trials Sub-types →
- Testis rhabdomyosarcoma 1 trial
- Breast rhabdomyosarcoma 0 trials
- Central nervous system rhabdomyosarcoma 0 trials
- Gallbladder rhabdomyosarcoma 0 trials
- Liver rhabdomyosarcoma 0 trials Sub-types →
- Mediastinum rhabdomyosarcoma 0 trials
- Oral rhabdomyosarcoma 0 trials
- Orbit rhabdomyosarcoma 0 trials Sub-types →
- Ovary rhabdomyosarcoma 0 trials
- Prostate rhabdomyosarcoma 0 trials Sub-types →
- Rectum rhabdomyosarcoma 0 trials Sub-types →
- Rhabdomyosarcoma of the cervix uteri 0 trials
- Rhabdomyosarcoma with mixed embryonal and alveolar features 0 trials
- Rhabdomyosarcoma, embryonal, 2 0 trials
- Uterine corpus rhabdomyosarcoma 0 trials
- Vaginal rhabdomyosarcoma 0 trials Sub-types →
-
Liposarcoma 58 trials · 83 incl. sub-types
19 sub-types
- Dedifferentiated liposarcoma 37 trials
- Myxoid/round cell liposarcoma 13 trials · 18 incl. sub-types Sub-types →
- Pleomorphic liposarcoma 8 trials
- Well-differentiated liposarcoma 5 trials Sub-types →
- Adult liposarcoma 0 trials
- Breast liposarcoma 0 trials
- Cutaneous liposarcoma 0 trials
- Esophagus liposarcoma 0 trials
- Fibroblastic liposarcoma 0 trials
- Gastric liposarcoma 0 trials
- Intracranial liposarcoma 0 trials
- Kidney liposarcoma 0 trials
- Larynx liposarcoma 0 trials
- Liposarcoma of bone 0 trials
- Liposarcoma of the ovary 0 trials Sub-types →
- Mediastinum liposarcoma 0 trials
- Mixed liposarcoma 0 trials
- Pediatric liposarcoma 0 trials
- Vulvar liposarcoma 0 trials
-
Angiosarcoma 37 trials · 82 incl. sub-types
19 sub-types
- Kaposi's sarcoma 45 trials Sub-types →
- Skin angiosarcoma 6 trials
- Breast angiosarcoma 1 trial
- Angiosarcoma of the scalp 0 trials
- Aorta angiosarcoma 0 trials
- Bone angiosarcoma 0 trials
- Central nervous system angiosarcoma 0 trials
- Conventional angiosarcoma 0 trials
- Gallbladder angiosarcoma 0 trials
- Liver angiosarcoma 0 trials
- Mediastinum angiosarcoma 0 trials
- Ovarian angiosarcoma 0 trials
- Pediatric angiosarcoma 0 trials
- Prostate angiosarcoma 0 trials
- Pulmonary artery leiomyosarcoma 0 trials
- Pulmonary vein leiomyosarcoma 0 trials
- Spleen angiosarcoma 0 trials
- Superior vena cava angiosarcoma 0 trials Sub-types →
- Thyroid gland angiosarcoma 0 trials
-
Rhabdoid tumor 63 trials · 75 incl. sub-types
5 sub-types
- Atypical teratoid rhabdoid tumor 35 trials · 36 incl. sub-types Sub-types →
- Rhabdoid tumor of the kidney 7 trials
- Extrarenal rhabdoid tumor 1 trial
- Familial rhabdoid tumor 0 trials · 1 incl. sub-types Sub-types →
- Striated muscle rhabdoid tumor 0 trials
-
Central nervous system sarcoma 2 trials · 74 incl. sub-types
12 sub-types
- Malignant peripheral nerve sheath tumor 36 trials · 38 incl. sub-types Sub-types →
- Atypical teratoid rhabdoid tumor 35 trials · 36 incl. sub-types Sub-types →
- Brain sarcoma 0 trials Sub-types →
- Central nervous system angiosarcoma 0 trials
- Central nervous system extraskeletal osteosarcoma 0 trials
- Central nervous system fibrosarcoma 0 trials
- Central nervous system leiomyosarcoma 0 trials Sub-types →
- Central nervous system rhabdomyosarcoma 0 trials
- Intracranial extraskeletal myxoid chondrosarcoma 0 trials
- Isolated melanotic schwannoma 0 trials
- Meningeal sarcoma 0 trials Sub-types →
- Spinal cord sarcoma 0 trials
-
Leiomyosarcoma 62 trials · 72 incl. sub-types
31 sub-types
- Leiomyosarcoma of the corpus uteri 9 trials Sub-types →
- Ovary leiomyosarcoma 2 trials
- Retroperitoneal leiomyosarcoma 2 trials
- Inflammatory leiomyosarcoma 1 trial
- Small intestine leiomyosarcoma 1 trial
- Bone leiomyosarcoma 0 trials
- Breast leiomyosarcoma 0 trials
- Central nervous system leiomyosarcoma 0 trials Sub-types →
- Colon leiomyosarcoma 0 trials
- Conventional leiomyosarcoma 0 trials
- Cutaneous leiomyosarcoma 0 trials
- Epithelioid leiomyosarcoma 0 trials Sub-types →
- Esophagus leiomyosarcoma 0 trials
- Fallopian tube leiomyosarcoma 0 trials
- Gallbladder leiomyosarcoma 0 trials
- Gastric leiomyosarcoma 0 trials
- Heart leiomyosarcoma 0 trials
- Kidney leiomyosarcoma 0 trials
- Laryngeal leiomyosarcoma 0 trials
- Leiomyosarcoma of the cervix uteri 0 trials
- Liver leiomyosarcoma 0 trials Sub-types →
- Lung leiomyosarcoma 0 trials
- Mediastinum leiomyosarcoma 0 trials
- Myxoid leiomyosarcoma 0 trials Sub-types →
- Prostate leiomyosarcoma 0 trials
- Pulmonary artery leiomyosarcoma 0 trials
- Pulmonary vein leiomyosarcoma 0 trials
- Rectum leiomyosarcoma 0 trials Sub-types →
- Superior vena cava leiomyosarcoma 0 trials
- Vagina leiomyosarcoma 0 trials
- Vulvar leiomyosarcoma 0 trials
-
Synovial sarcoma 53 trials
5 sub-types
- Biphasic synovial sarcoma 0 trials
- Breast synovial sarcoma 0 trials
- Fibrous synovial sarcoma 0 trials
- Mediastinum synovial sarcoma 0 trials
- Monophasic synovial sarcoma 0 trials Sub-types →
-
Undifferentiated pleomorphic sarcoma 48 trials
3 sub-types
-
Desmoplastic small round cell tumor 26 trials
-
Myxofibrosarcoma 21 trials
-
Fibrosarcoma 9 trials · 21 incl. sub-types
11 sub-types
- Dermatofibrosarcoma protuberans 11 trials Sub-types →
- Low grade fibromyxoid sarcoma 4 trials Sub-types →
- Conventional fibrosarcoma 0 trials · 2 incl. sub-types Sub-types →
- Pediatric fibrosarcoma 0 trials · 2 incl. sub-types Sub-types →
- Bone fibrosarcoma 0 trials
- Breast fibrosarcoma 0 trials
- Central nervous system fibrosarcoma 0 trials
- Heart fibrosarcoma 0 trials
- Kidney fibrosarcoma 0 trials
- Liver fibrosarcoma 0 trials
- Small intestinal fibrosarcoma 0 trials
-
Alveolar soft part sarcoma 20 trials
2 sub-types
- Cervical alveolar soft part sarcoma 0 trials
- Vulvar alveolar soft part sarcoma 0 trials
-
Epithelioid sarcoma 20 trials
4 sub-types
- Adult epithelioid sarcoma 0 trials
- Childhood epithelioid sarcoma 0 trials
- Peripheral epithelioid sarcoma 0 trials
- Proximal-type epithelioid sarcoma 0 trials Sub-types →
-
Retroperitoneal sarcoma 17 trials
1 sub-type
- Retroperitoneal leiomyosarcoma 2 trials
-
Clear cell sarcoma 14 trials · 16 incl. sub-types
1 sub-type
- Clear cell sarcoma of kidney 2 trials
-
Liver sarcoma 1 trial · 10 incl. sub-types
7 sub-types
- Undifferentiated (embryonal) sarcoma 9 trials
- Bile duct sarcoma 0 trials Sub-types →
- Liver angiosarcoma 0 trials
- Liver extraskeletal osteosarcoma 0 trials
- Liver fibrosarcoma 0 trials
- Liver leiomyosarcoma 0 trials Sub-types →
- Liver rhabdomyosarcoma 0 trials Sub-types →
-
Skin sarcoma 1 trial · 9 incl. sub-types
5 sub-types
- Skin angiosarcoma 6 trials
- Cutaneous undifferentiated pleomorphic sarcoma 2 trials
- Cutaneous leiomyosarcoma 0 trials
- Cutaneous liposarcoma 0 trials
- Skin lymphangiosarcoma 0 trials
-
SMARCA4-deficient sarcoma of thorax 8 trials
-
Kidney sarcoma 0 trials · 8 incl. sub-types
7 sub-types
- Rhabdoid tumor of the kidney 7 trials
- Clear cell sarcoma of kidney 2 trials
- Anaplastic sarcoma of the kidney 0 trials
- Kidney fibrosarcoma 0 trials
- Kidney leiomyosarcoma 0 trials
- Kidney liposarcoma 0 trials
- Kidney osteogenic sarcoma 0 trials
-
Extraskeletal myxoid chondrosarcoma 7 trials
1 sub-type
-
Intimal sarcoma 4 trials
-
Extraskeletal Ewing sarcoma 3 trials
-
Undifferentiated round cell sarcoma 3 trials
-
Breast sarcoma 2 trials · 3 incl. sub-types
7 sub-types
- Breast angiosarcoma 1 trial
- Breast extraskeletal osteosarcoma 0 trials
- Breast fibrosarcoma 0 trials
- Breast leiomyosarcoma 0 trials
- Breast liposarcoma 0 trials
- Breast rhabdomyosarcoma 0 trials
- Breast synovial sarcoma 0 trials
-
Extraosseous osteosarcoma 2 trials
7 sub-types
- Adult extraskeletal osteosarcoma 0 trials
- Breast extraskeletal osteosarcoma 0 trials
- Central nervous system extraskeletal osteosarcoma 0 trials
- Childhood extraosseous osteosarcoma 0 trials
- Kidney osteogenic sarcoma 0 trials
- Liver extraskeletal osteosarcoma 0 trials
- Mediastinal extraskeletal osteosarcoma 0 trials
-
Ovarian sarcoma 0 trials · 2 incl. sub-types
4 sub-types
- Ovary leiomyosarcoma 2 trials
- Liposarcoma of the ovary 0 trials Sub-types →
- Ovarian angiosarcoma 0 trials
- Ovary rhabdomyosarcoma 0 trials
-
Heart sarcoma 1 trial
3 sub-types
- Heart fibrosarcoma 0 trials
- Heart leiomyosarcoma 0 trials
- Malignant cardiac peripheral nerve sheath neoplasm 0 trials
-
Small intestinal sarcoma 0 trials · 1 incl. sub-types
2 sub-types
- Small intestine leiomyosarcoma 1 trial
- Small intestinal fibrosarcoma 0 trials
-
Testis sarcoma 0 trials · 1 incl. sub-types
1 sub-type
- Testis rhabdomyosarcoma 1 trial
-
Anus sarcoma 0 trials
2 sub-types
- Anus leiomyosarcoma 0 trials
- Anus rhabdomyosarcoma 0 trials
-
Bladder sarcoma 0 trials
-
Esophagus sarcoma 0 trials
2 sub-types
- Esophagus leiomyosarcoma 0 trials
- Esophagus liposarcoma 0 trials
-
Gallbladder sarcoma 0 trials
3 sub-types
- Gallbladder angiosarcoma 0 trials
- Gallbladder leiomyosarcoma 0 trials
- Gallbladder rhabdomyosarcoma 0 trials
-
Laryngeal sarcoma 0 trials
2 sub-types
- Laryngeal leiomyosarcoma 0 trials
- Larynx liposarcoma 0 trials
-
Lung sarcoma 0 trials
1 sub-type
- Lung leiomyosarcoma 0 trials
-
Mediastinum sarcoma 0 trials
7 sub-types
- Malignant melanocytic peripheral nerve sheath tumor of mediastinum 0 trials
- Mediastinal extraskeletal osteosarcoma 0 trials
- Mediastinum angiosarcoma 0 trials
- Mediastinum leiomyosarcoma 0 trials
- Mediastinum liposarcoma 0 trials
- Mediastinum rhabdomyosarcoma 0 trials
- Mediastinum synovial sarcoma 0 trials
-
Myxosarcoma 0 trials
-
Pancreas sarcoma 0 trials
-
Paranasal sinus sarcoma 0 trials
-
Penile sarcoma 0 trials
-
Prostate sarcoma 0 trials
4 sub-types
- Prostate angiosarcoma 0 trials
- Prostate leiomyosarcoma 0 trials
- Prostate rhabdomyosarcoma 0 trials Sub-types →
- Prostate stromal sarcoma 0 trials
-
Stromal sarcoma 0 trials
1 sub-type
- Prostate stromal sarcoma 0 trials
-
Thyroid sarcoma 0 trials
1 sub-type
- Thyroid gland angiosarcoma 0 trials
-
Trachea sarcoma 0 trials
-
Vagina sarcoma 0 trials
3 sub-types
- Endometrioid stromal sarcoma of the vagina 0 trials
- Vagina leiomyosarcoma 0 trials
- Vaginal rhabdomyosarcoma 0 trials Sub-types →
-
Vulva sarcoma 0 trials
5 sub-types
- Vulvar alveolar soft part sarcoma 0 trials
- Vulvar childhood botryoid-type embryonal rhabdomyosarcoma 0 trials
- Vulvar leiomyosarcoma 0 trials
- Vulvar liposarcoma 0 trials
- Vulvar proximal-type epithelioid sarcoma 0 trials
Most studied deeper sub-types
-
Could a shorter radiation zap before surgery be just as good for sarcoma patients?
Disease control OngoingThis study compares the usual 5-week radiation schedule before sarcoma surgery to a shorter 2-week course. Researchers want to see if the shorter course leads to similar wound healing and tumor control. About 168 adults with soft tissue sarcomas in the head, neck, trunk, or limbs…
Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Custom RNA vaccine aims to supercharge cancer immunotherapy
Disease control PausedThis early-phase trial tests a personalized RNA nanoparticle vaccine made from a patient's own tumor. The goal is to help anti-PD-1 immunotherapy work better in people with advanced melanoma or soft tissue sarcoma whose cancer has progressed on standard treatment. Up to 18 partic…
Phase 1 • Sponsor: University of Florida • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Virus plus radiation may shrink sarcomas before surgery
Disease control OngoingThis study tests whether a cancer-killing virus (T-VEC) combined with radiation can shrink soft tissue sarcomas before surgery. About 40 adults with newly diagnosed, removable sarcomas will receive the virus injected into the tumor plus radiation. The main goals are to see how ma…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug combo aims to stall rare Cancer's spread
Disease control OngoingThis study compares the drug palbociclib alone versus palbociclib plus cemiplimab in 77 people with advanced dedifferentiated liposarcoma that cannot be removed by surgery. Palbociclib blocks enzymes that help cancer cells grow, while cemiplimab boosts the immune system to attack…
Phase 2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Could fewer radiation sessions mean fewer complications for sarcoma patients?
Disease control OngoingThis phase 2 trial is testing a shorter, higher-dose radiation schedule given before surgery for soft tissue sarcoma of the arms, legs, or trunk. The goal is to see if this approach reduces wound complications after surgery while still controlling the cancer. About 122 patients a…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug cocktail aims to stop sarcoma from coming back
Disease control OngoingThis early-phase study tested the safety and best dose of adding bevacizumab to standard chemotherapy and radiation for people with soft tissue sarcoma that can be removed by surgery. The goal is to see if this combination can reduce the chance of the cancer returning after surge…
Phase 1 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New combo therapy aims to shrink Hard-to-Treat sarcomas
Disease control PausedThis early-phase trial tests whether adding the experimental drug zanzalintinib to two immunotherapy drugs (ipilimumab and nivolumab) is safe and can shrink tumors in people with metastatic soft tissue sarcoma. About 18 adults who have already tried 1 to 3 prior treatments will r…
Phase 1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for rare sarcomas: targeted pill attacks Cancer's DNA repair
Disease control OngoingThis study tests a drug called niraparib in people with advanced soft tissue sarcoma that has certain DNA repair gene changes. The goal is to see if the drug can stop or slow tumor growth. About 8 adults with inoperable or metastatic sarcoma will take niraparib pills and be monit…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for kids with rare cancers: drug targets tumor growth
Disease control OngoingThis phase 2 trial tests the drug cabozantinib in children and young adults with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. Cabozantinib works by blocking enzymes that help tumors grow and form blood vessels. The study a…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Promising combo tackles rare sarcoma in early trial
Disease control OngoingThis study tests a combination of two drugs, lurbinectedin and doxorubicin, in people with advanced soft-tissue sarcoma or leiomyosarcoma that cannot be cured with standard treatments. The first part finds a safe dose, and the second part compares the combination to lurbinectedin…
Phase 1/2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Engineered immune cells take aim at rare bone and soft tissue cancers
Disease control OngoingThis early-phase trial tests a new treatment called Attil12-T cell therapy for people with advanced soft tissue or bone sarcoma that has spread or cannot be removed. The therapy uses a patient's own immune cells, modified to target and attack the tumor. The main goals are to find…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New hope for kids with rare cancers: targeted drug selpercatinib tested in phase 2 trial
Disease control OngoingThis phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New combo therapy aims to shrink tumors in hard-to-treat cancers
Disease control OngoingThis study is testing whether adding an immune-boosting drug (BDB001) and targeted radiation to the immunotherapy atezolizumab can help control or shrink tumors in people with advanced solid tumors, including pancreatic, lung, bladder, and breast cancers. About 247 adults with th…
Phase 2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can an immune-boosting drug make chemotherapy more effective against sarcoma?
Disease control OngoingThis phase 2 trial is testing whether adding bintrafusp alfa, an experimental immunotherapy, to standard doxorubicin chemotherapy can help control advanced soft-tissue sarcoma. The study includes people with metastatic or unresectable tumors and looks at how well the combination …
Phase 2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Virus and radiation combo takes aim at tough sarcomas
Disease control OngoingThis phase 2 trial tests whether injecting a modified herpes virus (TVEC) directly into tumors, combined with radiation therapy before surgery, can shrink advanced soft tissue sarcomas. The study enrolled 2 adults with specific sarcoma types that could not be removed with clear m…
Phase 2 • Sponsor: John Rieth • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Targeted drug shows promise for kids with Tough-to-Treat cancers
Disease control OngoingThis study tested the drug ensartinib in 13 children and young adults (ages 1–21) whose cancers had come back or did not respond to treatment and had specific ALK or ROS1 gene changes. The goal was to see if the drug could shrink or stop tumor growth. While the drug targets cance…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Shorter radiation before sarcoma surgery: could it reduce wound problems?
Disease control OngoingThis phase 2 trial tests whether a shorter course (2-3 weeks) of proton or carbon ion radiation before surgery for extremity soft tissue sarcoma is safe and feasible. The main goal is to see if it reduces wound healing problems after surgery. The study enrolls 42 adults with rese…
Sponsor: University Hospital Heidelberg • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Could a few days of radiation replace weeks for sarcoma patients?
Disease control PausedThis study compares a shorter, more intense course of radiation (5 sessions) to the standard longer course (25 sessions) given before surgery for soft tissue sarcoma. The goal is to see if the shorter schedule is safe and effective at killing tumor cells. Thirty adults with sarco…
Phase 2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New radiation approach aims to tame sarcoma with fewer sessions
Disease control OngoingThis phase 2 trial is testing a shorter course of high-dose radiation (hypofractionated radiotherapy) for soft tissue sarcoma. The goal is to see if this approach can control the tumor for at least two years while reducing damage to nearby healthy tissue. About 48 adults with ino…
Phase 2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Cancer-Killing virus injected directly into tumors shows promise in Mid-Stage trial
Disease control OngoingThis study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…
Phase 2 • Sponsor: EpicentRx, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Experimental combo targets Hard-to-Treat sarcomas
Disease control OngoingThis study tests a combination of two drugs—HDM201 and pazopanib—in people with advanced or metastatic soft tissue sarcoma that has a normal p53 gene. The trial has two parts: first, finding the safest dose of HDM201 when given with a fixed dose of pazopanib, and second, checking…
Phase 1/2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Experimental cocktail aims to turn tumors against themselves
Disease control OngoingThis early-stage study tests whether a mix of immune-boosting drugs and targeted radiation can help the body fight advanced solid tumors that cannot be removed by surgery. About 14 adults with certain types of skin cancer, sarcoma, or breast cancer will receive the treatment dire…
Phase 1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with rare cancers: targeted drug larotrectinib tested in small trial
Disease control OngoingThis phase 2 trial is testing the drug larotrectinib in children and young adults (ages 1 to 21) with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have a specific genetic change called an NTRK fusion. The cancers have either come back after treatment…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy hopes to tame advanced cancers
Disease control OngoingThis early-phase trial tests several new drug combinations in people with advanced solid tumors (like stomach, ovarian, or liver cancer) that have spread and stopped responding to standard treatments. The goal is to find the safest dose and see if the drugs can help control the c…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug hope for rare sarcomas after chemo fails
Disease control OngoingThis study tests a daily oral drug called surufatinib in 47 people with advanced osteosarcoma or soft tissue sarcoma that has not responded to standard chemotherapy. The goal is to see if the drug can slow tumor growth and improve survival. Participants take the drug in 21-day cy…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Could your own tumor cells fight cancer? new trial tests immune cell therapy
Disease control OngoingThis phase 2 trial tests a treatment called LN-145, made from a patient's own immune cells taken from their tumor. These cells are grown in a lab and then given back to the patient to attack the cancer. The study includes people with ovarian cancer, triple-negative breast cancer,…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Vitamin c and chemo: new hope for Hard-to-Treat sarcomas?
Disease control OngoingThis early-phase trial tests whether adding high-dose vitamin C (ascorbate) to the chemotherapy drug gemcitabine can help adults with advanced soft tissue or bone sarcoma that cannot be surgically removed or has spread. About 30 participants will receive the combination intraveno…
Early phase 1 • Sponsor: University of Iowa • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Drug combo shows promise in slowing rare sarcomas
Disease control OngoingThis phase 2 trial tests two oral drugs, ribociclib and everolimus, in people with advanced dedifferentiated liposarcoma or leiomyosarcoma who have had at least one prior treatment. The goal is to see if the combination can stop or slow tumor growth. About 48 participants will ta…
Phase 2 • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug cocktail shows promise for rare sarcomas
Disease control OngoingThis phase II trial tests whether combining cabozantinib (a targeted therapy) with temozolomide (a chemotherapy drug) can slow tumor growth in people with advanced leiomyosarcoma or other soft tissue sarcomas that cannot be surgically removed or have spread. About 96 participants…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Engineered immune cells take aim at childhood cancers in early trial
Disease control OngoingThis early-phase study tests a personalized cell therapy for children and young adults (up to age 26) with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, modified to recognize and attack a protein called B…
Phase 1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug cocktail shows promise against rare sarcomas
Disease control OngoingThis study tests whether adding the targeted drug cabozantinib to immunotherapy (ipilimumab and nivolumab) works better than immunotherapy alone for people with advanced soft tissue sarcoma that has spread. About 66 adults with specific sarcoma types will take part. The goal is t…
Phase 2 • Sponsor: National Cancer Institute LAO • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Immunotherapy combo shows promise against sarcoma in early trial
Disease control OngoingThis phase 2 trial tests whether adding the immunotherapy drug retifanlimab to standard chemotherapy before surgery can improve outcomes for people with resectable soft-tissue sarcoma. About 66 participants will receive either chemotherapy alone or chemotherapy plus retifanlimab.…
Phase 2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug cocktail shows promise in slowing rare sarcoma
Disease control OngoingThis study tests whether adding two immunotherapy drugs (zalifrelimab and balstilimab) to standard chemotherapy (doxorubicin) can help control advanced or metastatic soft tissue sarcoma for longer. About 65 adults with sarcoma that cannot be removed by surgery will receive the co…
Phase 2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Tumor 'Avatars' in a dish could help pick better chemo for kids with rare cancers
Disease control By invitation onlyThis study is testing a new way to choose chemotherapy for children with high-risk or relapsed soft tissue sarcomas. Doctors grow a miniature version of the patient's tumor in the lab (called an organoid) and test different drugs on it to see which works best. The goal is to see …
Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Radioactive seeds zapped tumors from inside – early trial shows promise
Disease control OngoingThis study is testing a device called DaRT that delivers alpha radiation directly into tumors. It is for people with skin cancer, mouth tumors, or superficial soft tissue sarcoma who have not responded to other treatments or cannot have standard therapy. The goal is to see if the…
Sponsor: Alpha Tau Medical LTD. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Can a Patient's own immune cells beat childhood cancers that Won't quit?
Disease control OngoingThis early-stage trial tests a treatment made from a patient's own immune cells, called tumor-infiltrating lymphocytes (TIL). Doctors remove a piece of the tumor, grow the immune cells in a lab, and then infuse them back into the patient to attack the cancer. The study includes 4…
Phase 1 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Oxygen therapy tested to speed healing after sarcoma surgery
Disease control OngoingThis pilot study looks at whether hyperbaric oxygen therapy (breathing pure oxygen in a pressurized chamber) can help wounds heal better after surgery and radiation for soft tissue sarcoma. About 20 adults with sarcoma in the leg will be randomly assigned to receive either the ox…
Phase 4 • Sponsor: Duke University • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Supercharged immune cells take on childhood cancers
Disease control OngoingThis early-phase trial tests a new type of cell therapy for children and young adults with solid tumors that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, which are trained in the lab to recognize and attack multiple cancer…
Phase 1 • Sponsor: Children's National Research Institute • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Experimental combo aims to boost immune attack on sarcoma before surgery
Disease control OngoingThis early-phase study tests the safety of combining two immunotherapy drugs—nivolumab and BO-112—given before surgery for soft tissue sarcoma that can be removed. About 14 adults with certain sarcoma types will receive these drugs to see if they help the immune system fight the …
Phase 1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Sharper aim: new radiation technique seeks to spare healthy tissue in kids with tumors
Disease control OngoingThis study tests a precise radiation technique called image-guided radiotherapy (IGRT) for children and young adults with bone or soft tissue tumors. By using CT, MRI, and PET scans to pinpoint the tumor, doctors aim to deliver radiation more accurately and reduce damage to healt…
Phase 2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Could less radiation be just as good for sarcoma?
Disease control OngoingThis study is testing whether giving a lower dose of radiation to a smaller area after surgery for soft tissue sarcoma works as well as the standard approach. The goal is to control the cancer while causing fewer long-term side effects. The trial includes 65 adults who had their …
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Immunotherapy plus radiation shows promise against rare sarcomas
Disease control OngoingThis Phase 2 trial tests whether adding the immunotherapy drug atezolizumab to standard radiotherapy improves outcomes for people with soft tissue sarcoma. About 62 participants will receive treatment in different sequences: radiation before or after surgery, combined with atezol…
Phase 2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Hitchhiking drug targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-stage trial tests a new drug called SON-1010 in 42 adults with advanced solid tumors that have spread or cannot be removed. The drug is designed to hitch a ride on a blood protein called albumin to deliver an immune-boosting signal (IL-12) directly to the tumor area. T…
Phase 1 • Sponsor: Sonnet BioTherapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Can fewer, stronger radiation doses before sarcoma surgery reduce wound problems?
Disease control OngoingThis phase II trial tests a shorter course of radiation (hypofractionated) given before surgery for soft tissue sarcoma of the arms, legs, or trunk. The goal is to see if this approach reduces major wound complications after surgery. About 120 adults with localized, resectable sa…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Virus and radiation combo takes aim at rare sarcomas
Disease control OngoingThis early-phase trial tests whether injecting a cancer-fighting virus (T-VEC) directly into tumors, along with standard radiation, is safe and tolerable for people with advanced soft tissue sarcoma. About 8 participants will receive the combination before surgery. The study prim…
Phase 1/2 • Sponsor: John Rieth • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New Vaccine-Immunotherapy combo targets multiple cancers in early trial
Disease control OngoingThis phase 1 trial tests a vaccine (p53MVA) that trains the immune system to attack cancer cells with a p53 mutation, given together with the immunotherapy drug pembrolizumab (Keytruda). The study includes 11 people with advanced solid tumors like lung, head and neck, liver, kidn…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New oral drug shows promise for kids with rare RET-Driven cancers
Disease control OngoingThis study tests an oral drug called selpercatinib (LOXO-292) in children with advanced solid or brain tumors that have a specific RET gene change. The trial has two parts: first finding a safe dose, then measuring how many children's tumors shrink. About 36 children whose cancer…
Phase 1/2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Could a 5-Day radiation blast replace weeks of treatment for sarcoma?
Disease control OngoingThis study tests a shorter, 5-day course of radiation before surgery for soft tissue sarcoma, instead of the usual several weeks. The goal is to see if patients choose this option and if it works as well for controlling the tumor. About 16 adults with sarcoma in an arm, leg, or t…
Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Triple therapy shows promise in shrinking sarcomas before surgery
Disease control OngoingThis study tests whether combining an immunotherapy drug (pembrolizumab) with another immune-boosting protein (eftilagimod alpha) and radiation therapy can shrink soft tissue sarcomas before surgery. About 40 adults with high-risk, non-spread sarcomas will receive this combinatio…
Phase 2 • Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Engineered immune cells take on childhood cancers in first human test
Disease control OngoingThis early-stage trial tests a new type of immunotherapy for children and young adults with solid tumors that have not responded to standard treatments. The therapy uses the patient's own immune cells (T cells) that are genetically modified to recognize and attack cancer cells ca…
Phase 1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New drug cocktail aims to shrink Hard-to-Treat sarcomas
Disease control OngoingThis study tests whether adding two immunotherapy drugs (nivolumab and ipilimumab) to the targeted therapy cabozantinib can shrink tumors better than cabozantinib alone in people with metastatic soft tissue sarcoma. About 105 adults whose cancer has worsened after prior treatment…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New combo therapy targets hard-to-treat liposarcoma
Disease control OngoingThis study tests whether combining two drugs—etrumadenant and zimberelimab—can shrink or slow advanced dedifferentiated liposarcoma that has returned, spread, or can't be removed by surgery. About 16 adults with this rare cancer will receive the treatment. The goal is to see how …
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Aspirin vs. heparin: which prevents clots better after cancer bone surgery?
Disease control By invitation onlyThis study compares two common blood thinners—aspirin and enoxaparin (Lovenox)—to see which works better at preventing dangerous blood clots after surgery for bone cancer or cancer that has spread to the bone. About 2,868 adults having pelvic or leg surgery for these conditions w…
Phase 4 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New combo attack on sarcoma: immunotherapy meets precision radiation
Disease control OngoingThis pilot study tests whether combining the immunotherapy drug pembrolizumab with stereotactic ablative radiotherapy (SBRT) is feasible for people with advanced or metastatic soft-tissue sarcoma. Nine participants with disease that cannot be surgically removed will receive both …
Early phase 1 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Cancer combo trial pulled before it even started
Disease control CancelledThis study was designed to test a combination of two drugs, Ezabenlimab and BI907828, in people with advanced solid tumors like sarcoma, lung cancer, and breast cancer. The goal was to see if the treatment could control the disease for at least 24 weeks. However, the trial was wi…
Phase 2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 26, 2026 13:13 UTC
-
Could prehab training during chemo strengthen young cancer patients?
Symptom relief OngoingThis study tests whether a supervised strength and balance exercise program is feasible for children and teens undergoing chemotherapy for bone or soft tissue sarcoma in the lower leg. The goal is to see if this 'prehabilitation' can reduce muscle and bone weakening, and improve …
Sponsor: Technical University of Munich • Aim: Symptom relief
Last updated Aug 20, 2026 00:00 UTC
-
Experimental procedure aims to shrink untreatable childhood tumors
Symptom relief CancelledThis study planned to test a procedure called transarterial embolization in children aged 2-18 with incurable soft tissue sarcomas. The goal was to block blood flow to tumors using tiny particles, potentially slowing growth or easing symptoms. However, the trial was withdrawn bef…
Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Choice or fixed? study tests how to get better data from young cancer patients
Knowledge-focused OngoingThis study enrolls 400 adolescents and young adults (ages 18-39) recently diagnosed with various cancers. Participants are randomly assigned to either choose which health-related questions they answer or receive a fixed set of questions. The goal is to see if giving patients a ch…
Early phase 1 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
Can young sarcoma survivors fully recover? a new study investigates
Knowledge-focused OngoingThis study looks at children, teens, and young adults who finished treatment for bone or soft tissue sarcoma in the lower leg or thigh 1 to 5 years ago. It measures muscle size, body composition, strength, mobility, and quality of life to see if they have lasting physical limitat…
Sponsor: Technical University of Munich • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
New imaging technique sheds light on oxygen in sarcomas
Knowledge-focused OngoingThis study uses a special PET scan with a tracer called FAZA, combined with MRI, to measure oxygen levels (hypoxia) in soft tissue sarcoma tumors. About 70 adults with high-risk sarcoma will get the scan before treatment or surgery. The goal is to learn more about tumor biology, …
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Can DNA tests pick the right cancer drug for kids?
Knowledge-focused OngoingThis study screens children and teens with advanced solid tumors, lymphomas, or histiocytic disorders to find genetic changes in their cancer cells. Participants undergo biopsies and scans to identify mutations that can be targeted by specific drugs. The goal is to see if matchin…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Blood test may replace painful biopsies for sarcoma patients
Knowledge-focused OngoingThis study is looking for 50 adults with soft tissue sarcoma to see if a blood test can detect tumor DNA (ctDNA) as well as a standard tissue biopsy. Currently, doctors need to take a piece of the tumor to diagnose and monitor sarcoma, which can be risky and hard to do. By compar…
Sponsor: Medical College of Wisconsin • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Can a protein predict chemo success in sarcoma?
Knowledge-focused OngoingThis study looks at whether a protein called TOPO2A can help predict if the chemotherapy drugs doxorubicin or Doxil will shrink tumors in people with soft tissue sarcoma. About 24 patients whose next treatment plan includes one of these drugs will provide tumor tissue for testing…
Sponsor: Fox Chase Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Can Oxygen-Sensing MRI help personalize childhood cancer treatment?
Knowledge-focused By invitation onlyThis study tests whether special MRI scans can measure oxygen levels inside children's sarcoma tumors. Low oxygen (hypoxia) can make tumors harder to treat. The scans are done before and after standard chemotherapy or radiation to see if they can predict how well the tumor respon…
Phase 1 • Sponsor: The Hospital for Sick Children • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Study tracks how sarcoma surgery impacts Seniors' daily function
Knowledge-focused OngoingThis study looks at how surgery for soft tissue sarcoma in the leg affects the daily function of patients aged 70 and older. Researchers will use questionnaires to measure quality of life and physical ability before and after treatment. The goal is to identify factors that help p…
Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Cancer tissue bank aims to fuel future discoveries
Knowledge-focused OngoingThis study collects leftover tissue, blood, and other fluid samples from 6,000 people with benign or malignant tumors of the soft tissue, gastrointestinal tract, or abdomen. Researchers will use these samples in lab studies to better understand the causes, prevention, diagnosis, …
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
DNA bank aims to unlock secrets of family cancer clusters
Knowledge-focused OngoingThis study collects blood and saliva samples from people with cancer and their relatives to build a DNA bank. Researchers hope to better understand how cancer runs in families. About 992 participants are expected to join. The samples will be stored and analyzed later for genetic …
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
New risk tool aims to take the guesswork out of sarcoma treatment choices
Knowledge-focused OngoingThis study tests a tool called PERSARC that gives soft-tissue sarcoma patients personalized information about the risks and benefits of different treatment options. 120 adults with high-grade sarcoma in their arms or legs will either get standard care or care using PERSARC. The g…
Sponsor: Leiden University Medical Center • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:17 UTC
-
New study tracks hidden health problems in cancer survivors
Knowledge-focused OngoingThis study follows 500 adults aged 18-65 who completed chemotherapy for certain cancers and are in remission. Researchers will check for 19 possible late side effects over 5 years, including heart, lung, and hormone problems. The goal is to catch these issues early and connect pa…
Sponsor: Centre Leon Berard • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:33 UTC